Literature DB >> 28275409

PAI-1 Inhibition - Another Therapeutic Option for Cardiovascular Protection.

Monica Mariana Baluta1, Marius Marcian Vintila1.   

Abstract

Current research suggest that plasminogen activator inhibitor type 1 (PAI-1) is an important contributor to a number of disease processes. The aim of the current paper is to emphasize the deleterious effects of PAI-1 on cardiovascular diseases development and progression. The plasminogen system is known by its role in hemostasis and thrombosis regulation. Lifestyle changes and pharmacological treatment can regulate PAI-1 levels and functions. Some pharmacologic agents currently used in the management of atherosclerosis and its complications can counteract the deleterious effects of PAI-1.

Entities:  

Year:  2015        PMID： 28275409      PMCID： PMC5327810     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN： 1841-9038


  34 in total

Review 1.  Exercise and physical activity: clinical outcomes and applications.

Authors:  Peter Kokkinos; Jonathan Myers
Journal:  Circulation       Date:  2010-10-19       Impact factor: 29.690

2.  Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production.

Authors:  N J Brown; K S Kim; Y Q Chen; L S Blevins; J H Nadeau; S G Meranze; D E Vaughan
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

3.  Pentoxifylline lowers plasminogen activator inhibitor 1 levels in obese individuals: a pilot study.

Authors:  James A S Muldowney; Qingxia Chen; Dana L Blakemore; Douglas E Vaughan
Journal:  Angiology       Date:  2012-02-17       Impact factor: 3.619

4.  Hemostasis parameters disturbances in healthy individuals with prehypertension.

Authors:  Dimitris Papadopoulos; Iordanis Mourouzis; Athanasia Kotrotsou; Urania Papazachou; Elias Sanidas; Kostas Tsioufis; Thomas Makris
Journal:  Clin Exp Hypertens       Date:  2012-06-19       Impact factor: 1.749

5.  Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators.

Authors:  D E Vaughan; J L Rouleau; P M Ridker; J M Arnold; F J Menapace; M A Pfeffer
Journal:  Circulation       Date:  1997-07-15       Impact factor: 29.690

6.  Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with type 2 diabetes risk.

Authors:  Luqian Zhao; Ping Huang
Journal:  Int J Clin Exp Med       Date:  2013-09-01

7.  Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.

Authors:  Amanda E Boe; Mesut Eren; Sheila B Murphy; Christine E Kamide; Atsuhiko Ichimura; David Terry; Danielle McAnally; Layton H Smith; Toshio Miyata; Douglas E Vaughan
Journal:  Circulation       Date:  2013-10-03       Impact factor: 29.690

8.  Plasminogen activator inhitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study.

Authors:  Juho R H Raiko; Mervi Oikonen; Maria Wendelin-Saarenhovi; Niina Siitonen; Mika Kähönen; Terho Lehtimäki; Jorma Viikari; Antti Jula; Britt-Marie Loo; Risto Huupponen; Liisa Saarikoski; Markus Juonala; Olli T Raitakari
Journal:  Atherosclerosis       Date:  2012-07-16       Impact factor: 5.162

9.  17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women.

Authors:  Mias Pretorius; Gary P van Guilder; Raul J Guzman; James M Luther; Nancy J Brown
Journal:  Hypertension       Date:  2008-02-07       Impact factor: 10.190

10.  Concomitant administration of different doses of simvastatin with ivabradine influence on PAI-1 and heart rate in normo- and hypercholesterolaemic rats.

Authors:  Jacek Owczarek; Magdalena Jasińska-Stroschein; Daria Orszulak-Michalak
Journal:  ScientificWorldJournal       Date:  2012-05-03
View more
  7 in total

1.  Upregulation of Plasminogen Activator Inhibitor-1 in Irradiated Recipient Arteries and Veins from Free Tissue Transfer Reconstruction in Cancer Patients.

Authors:  Bjorn O Eriksson; Caroline Gahm; Martin Halle
Journal:  Mediators Inflamm       Date:  2018-10-04       Impact factor: 4.711

Review 2.  Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Front Cardiovasc Med       Date:  2020-12-22

3.  Assessment of histological characteristics, imaging markers, and rt-PA susceptibility of ex vivo venous thrombi.

Authors:  Samuel A Hendley; Alexey Dimov; Aarushi Bhargava; Erin Snoddy; Daniel Mansour; Rana O Afifi; Geoffrey D Wool; Yuanyuan Zha; Steffen Sammet; Zheng Feng Lu; Osman Ahmed; Jonathan D Paul; Kenneth B Bader
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.379

4.  Adipokine Profiling in Adult Women With Central Obesity and Hypertension.

Authors:  Rashmi Supriya; Benjamin Y Yung; Angus P Yu; Paul H Lee; Christopher W Lai; Kenneth K Cheng; Suk Y Yau; Lawrence W C Chan; Sinead Sheridan; Parco M Siu
Journal:  Front Physiol       Date:  2018-03-27       Impact factor: 4.566

5.  RNA sequencing of whole blood in dogs with primary immune-mediated hemolytic anemia (IMHA) reveals novel insights into disease pathogenesis.

Authors:  Corie Borchert; Adam Herman; Megan Roth; Aimee C Brooks; Steven G Friedenberg
Journal:  PLoS One       Date:  2020-10-22       Impact factor: 3.240

Review 6.  A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

7.  Efficacy of nobiletin in improving hypercholesterolemia and nonalcoholic fatty liver disease in high-cholesterol diet-fed mice.

Authors:  Young-Je Kim; Dae Seong Yoon; Un Ju Jung
Journal:  Nutr Res Pract       Date:  2021-03-11       Impact factor: 1.926
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.